Vericel Corporation (VCEL)
| Market Cap | 1.79B |
| Revenue (ttm) | 153.82M |
| Net Income (ttm) | 214,000 |
| Shares Out | 46.82M |
| EPS (ttm) | 0.01 |
| PE Ratio | 7,662.00 |
| Forward PE | 67.11 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 372,722 |
| Open | 42.50 |
| Previous Close | 40.19 |
| Day's Range | 37.37 - 40.71 |
| 52-Week Range | 22.93 - 68.94 |
| Beta | 1.94 |
| Analysts | Strong Buy |
| Price Target | 58.96 (+53.9%) |
| Earnings Date | Nov 9, 2021 |
About VCEL
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-de...
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for Vericel stock is "Strong Buy." The 12-month stock price forecast is 58.96, which is an increase of 53.90% from the latest price.
News
Vericel to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum on Nov...
CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Cola...
Vericel Corporation (VCEL) Reports Q3 Loss, Misses Revenue Estimates
Vericel Corporation (VCEL) delivered earnings and revenue surprises of -266.67% and -11.12%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: Vericel Q3 Earnings
Vericel (NASDAQ:VCEL) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM. Here's what investors need to know about the announcement.
Vericel Reports Third Quarter 2021 Financial Results
Third Quarter Total Net Revenue of $34.5 Million
Earnings Preview: Vericel Corporation (VCEL) Q3 Earnings Expected to Decline
Vericel Corporation (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vericel to Report Third-Quarter 2021 Financial Results on November 9, 2021
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following ...
How to Invest in Biotech Stocks in a Bear Market
Hint: it doesn't really matter what kind of market it is.
Vericel Expands Executive Leadership Team and Announces Appointment of Patrick Fowler as Senior Vice President, Corpo...
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, announced the appointment of ...
Vericel Corporation (VCEL) Reports Q2 Loss, Tops Revenue Estimates
Vericel Corporation (VCEL) delivered earnings and revenue surprises of -33.33% and 7.04%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Vericel Reports Second Quarter 2021 Financial Results and Raises Full-Year 2021 Revenue Guidance
Second Quarter Total Net Revenue Increased 97% to $39.5 Million
Will Vericel Corporation (VCEL) Report Negative Earnings Next Week? What You Should Know
Vericel Corporation (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vericel to Report Second-Quarter 2021 Financial Results on August 4, 2021
CAMBRIDGE, Mass., July 21, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following ...
Bear of the Day: Vericel (VCEL)
Restoring cartilage in sports medicine and rebuilding skin after severe burns gave this small-cap big upside
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vericel Corporation - VCEL
NEW YORK, July 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vericel Corporation ("Vericel" or the "Company") (NASDAQ: VCEL). Such investors are advised to co...
Vericel to Present at the Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021
CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Cola...
Why Vericel Tumbled by Nearly 15% on Tuesday
The FDA says "no" to the company's NexoBrid -- for now.
Why Shares Of MediWound And Vericel Fell On Tuesday
Shares of MediWound (NASDAQ: MDWD) and its development partner, Vericel Corporation (NASDAQ: VCEL), are trading lower after MediWound received a Complete Response Letter from the FDA for its NexoBrid Bi...
FDA Strikes Off MediWound - Vericel's NexoBrid Biologics License Application; Stocks Drop
Vericel Corporation's (NASDAQ:VCEL) development partner, MediWound Ltd (NASDAQ:MDWD), received a complete response letter from FDA regarding the NexoBrid application seeking approval for eschar removal ...
Vericel Provides Regulatory Update for NexoBrid
CAMBRIDGE, Mass., June 29, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that its devel...
Vericel to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021
CAMBRIDGE, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Cola...
Vericel Announces Appointment of Lisa Wright to Board of Directors
CAMBRIDGE, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointmen...
Vericel to Present at the Canaccord Genuity Virtual Musculoskeletal Conference on Thursday, May 20, 2021
CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colan...
Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates
Vericel Corporation (VCEL) delivered earnings and revenue surprises of -16.67% and 8.24%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: Vericel Q1 Earnings
Shares of Vericel (NASDAQ:VCEL) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share rose 30.00% year over year to ($0.07), which missed the estimate of ($0.04).
Vericel Reports First Quarter 2021 Financial Results and Raises Full-Year 2021 Revenue Guidance
First Quarter Total Net Revenue Increased 30% to $34.6 Million